Sarah Boyce brings to Avidity extensive experience in the life sciences industry, where she has built global organizations and brought to patients a number of innovative therapies, including Tegsedi®️️, Waylivra®️️, Soliris®️️, Gleevec®️️ and Tasigna®️️. She most recently served as President and a member of the board of directors of Akcea Therapeutics, where she led commercialization of the company’s rare disease products. Prior to joining Akcea in April 2018, Ms. Boyce held multiple executive-level roles at leading pharma and biotech companies including Ionis Pharmaceuticals, Forest Laboratories, Alexion Pharmaceuticals, Novartis Oncology and Roche. Ms. Boyce currently serves as a member of the board of directors at OmniAb, Inc. She received a B.S. degree in microbiology from the University of Manchester, England.